Chronic Kidney Disease
In this Future Leader Q&A, Dr Ignacio Portales-Castillo reflects on his path from rural primary care in Mexico to physician-scientist at Washington University School of Medicine in St. Louis. He shares how formative patient encounters and exceptional mentors shaped his passion for bone and mineral disorders in chronic kidney disease, how he strives to balance an intense research and clinical workload with family life, and why he believes the future of nephrology–endocrinology lies in both innovative therapies and sustainable, patient-centred care.
In this Future Leader Q&A, Dr Sourabh Sharma, nephrologist and transplant physician, discusses the transformative role of mentorship, advances in transplantation and diabetic kidney disease, and his vision for equitable, patient-centred renal care.
As touchENDOCRINOLOGY approaches 20 years of providing education for busy endocrinologists, we are looking to the future—and it certainly looks bright!
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Finerenone (a selective nonsteroidal mineralocorticoid receptor antagonist) and the SGLT2 inhibitor empagliflozin may reduce both kidney and cardiovascular risks in people with chronic kidney disease and type 2 diabetes. It is unknown whether dual therapy with finerenone and empagliflozin is superior ...
There is a high unmet need for new treatments to preserve kidney function and delay kidney disease progression in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). In this touchENDOCRINOLOGY interview, Prof. Jennifer Green (Duke University School ...
SUSTAIN 6 and PIONEER 6 investigated the effects of semaglutide versus placebo on major adverse cardiovascular events (MACE). The current post hoc analysis investigated the association between baseline kidney function and risk of MACE, and the effect of semaglutide on risk of ...
Chronic kidney disease (CKD) is a common diabetes-related complication among type 2 diabetes (T2DM) patients, with a high prevelance within primary care settings. In this touchENDOCRINOLOGY interview, we speak with Dr Sara (Mandy) Reece (Philadelphia College of Osteopathic Medicine (PCOM), ...
The current treatment options for chronic kidney disease in patients with type 2 diabetes is discussed by Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands). Also discussed is the mechanism of tirzepatide, a novel once-weekly medication, which has shown to ...
A pre-specific exploratory analysis of SURPASS-4 evaluated the progression to pre-specified kidney endpoints between tirzepatide and titrated daily insulin glargine in chronic kidney disease. Professor Hiddo Heerspink (University Medical Center Groningen, Groningen, Netherlands) discusses the outcome of the analysis and ...
The combined use of finerenone and glucagon-like peptide-1 receptor agonist (GLP-1RA) for chronic kidney disease (CKD) and type 2 diabetes (T2D) was studied in the FIDELITY analysis, and is discussed by Professor Peter Rossing (Steno Diabetes Center, Copenhagen, Denmark). ...
Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease. Find out more at: https://www.kidneyresearchuk.org/ Support: Published in collaboration ...
Kidney Research UK in collaboration with Dr James Burton highlight the unmet needs in research, the urgency and importance of transforming treatments for people living with kidney disease. Find out more at: https://www.kidneyresearchuk.org/ Support: Published in collaboration ...
Chronic kidney disease (CKD) represents one of the greatest future public health challenges due, among other consequences, to its elevated burden on economic and human resources within healthcare systems.1Â Moreover, the rapid growth of type 2 diabetes mellitus (T2DM) results ...
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
